O F Ikpatt1, R Ndoma-Egba. 1. Department of Pathology, University of Turku, Kiinamyllnkatu 10, FIN-20520, Finland. ofrikpatt@yahoo.com
Abstract
BACKGROUND: Expression of oestrogen receptors (ER) and progesterone receptors (PR) in breast carcinomas identifies patients that are more likely to respond to adjuvant therapy. OBJECTIVES: Our aim was to evaluate the prevalence and prognostic value of histologically confirmed ER and PR immunoreactivity in breast carcinoma seen at Calabar, Nigeria. DESIGN: Cross sectional study. SETTING: University of Calabar Teaching Hospital, Nigeria. SUBJECT: Sections of formalin-fixed, paraffin-embedded samples from 129 breast carcinomas were immunostained for ER and PR. RESULTS: ER and PR were immunohistochemically detected in 24.0% and 13.9%, respectively, of the breast carcinomas. The staining results were significantly associated, though negatively, with the axillary lymph node status, clinical stage, and histological grade. In survival analysis of the whole material, neither ER nor PR positivity showed any prognostic value. In the premenopausal group, both ER and PR showed a prognostic potential. However, they had no independent prognostic value. CONCLUSION: Further studies to assess the frequency and prognostic values of these hormone receptors in breast cancers, after standardized processing and a longer follow up period may be necessary to validate these findings. Furthermore, a consensus must be developed for scoring and reporting ER/PR in Nigerian material.
BACKGROUND: Expression of oestrogen receptors (ER) and progesterone receptors (PR) in breast carcinomas identifies patients that are more likely to respond to adjuvant therapy. OBJECTIVES: Our aim was to evaluate the prevalence and prognostic value of histologically confirmed ER and PR immunoreactivity in breast carcinoma seen at Calabar, Nigeria. DESIGN: Cross sectional study. SETTING: University of Calabar Teaching Hospital, Nigeria. SUBJECT: Sections of formalin-fixed, paraffin-embedded samples from 129 breast carcinomas were immunostained for ER and PR. RESULTS: ER and PR were immunohistochemically detected in 24.0% and 13.9%, respectively, of the breast carcinomas. The staining results were significantly associated, though negatively, with the axillary lymph node status, clinical stage, and histological grade. In survival analysis of the whole material, neither ER nor PR positivity showed any prognostic value. In the premenopausal group, both ER and PR showed a prognostic potential. However, they had no independent prognostic value. CONCLUSION: Further studies to assess the frequency and prognostic values of these hormone receptors in breast cancers, after standardized processing and a longer follow up period may be necessary to validate these findings. Furthermore, a consensus must be developed for scoring and reporting ER/PR in Nigerian material.
Authors: Louise A Brinton; Jonine D Figueroa; Baffour Awuah; Joel Yarney; Seth Wiafe; Shannon N Wood; Daniel Ansong; Kofi Nyarko; Beatrice Wiafe-Addai; Joe Nat Clegg-Lamptey Journal: Breast Cancer Res Treat Date: 2014-03-07 Impact factor: 4.872
Authors: A O Adisa; O A Arowolo; A A Akinkuolie; N A Titiloye; O I Alatise; O O Lawal; A R K Adesunkanmi Journal: Afr Health Sci Date: 2011-06 Impact factor: 0.927
Authors: Ashley M Burson; Amr S Soliman; Twalib A Ngoma; Julius Mwaiselage; P Ogweyo; Mohab S Eissa; Subhojit Dey; Sofia D Merajver Journal: Breast Dis Date: 2010
Authors: Michael N Okobia; Clareann H Bunker; Seymour J Garte; Joseph M Zmuda; Emmanuel R Ezeome; Stanley Nc Anyanwu; Emmanuel Eo Uche; Usifo Osime; Joseph Ojukwu; Lewis H Kuller; Robert E Ferrell; Emanuela Taioli Journal: Infect Agent Cancer Date: 2009-02-10 Impact factor: 2.965
Authors: D Huo; C A Adebamowo; T O Ogundiran; E E Akang; O Campbell; A Adenipekun; S Cummings; J Fackenthal; F Ademuyiwa; H Ahsan; O I Olopade Journal: Br J Cancer Date: 2008-02-26 Impact factor: 7.640